ABSTRACT
In this article, we present the follow-up and treatment process of neutropenia, which develops during COVID-19 infection in a healthy adult and lasts for approximately 45 days. When the patient applied with the complaints of weakness and joint pain, the PCR test was positive and neutropenia and lymphopenia were detected in the laboratory examination. Granulocyte-Colony Stimulating Factor (G-CSF) treatment was started in order to prevent the development of secondary infection to the patient, who was evaluated for additional medical treatment for neutropenia while the COVID-19 treatment was continuing. However, it was observed that neutropenia returned to normal after 1.5 months. Neutropenia secondary to COVID-19 infection can be seen in healthy adults and it is thought that the use of G-CSF in the treatment will be beneficial. © 2022, Pamukkale University. All rights reserved.
ABSTRACT
In December 2019, a novel coronavirus outbreak spread rapidly all over the world. The virus is known to be neuroinvasive, but much is still unknown. In this study, we aimed to pres-ent the main neurologic symptoms in patients who were diagnosed with coronavirus disease 2019 (COVID-19). The study was conducted retrospectively by phoning 156 patients in Turkey diagnosed with COVID-19 through real-time polymerase chain reaction;only 100 patients could be reached. Data about their demographics, initial symptoms, neurological symptoms, and sleeping habits were collected. During the disease process, 66% had at least one neurological symptom, 55% had central nervous system symptoms, 42% had peripheral nervous system symptoms, and 64% had sleep disturbances and myalgia. Impaired consciousness, smell and taste impairments, and sleep disturbances were significantly higher in patients with positive chest computed tomography imaging (p < 0.05). Neurological symptoms were observed in COVID-19, as in other coronaviruses. Headache in particular was the most common symptom in our population. In patients with respiratory system findings, the detec-tion of certain neurological symptoms such as smell-taste impairments, impaired consciousness, and sleep disorders were more common. We concluded that COVID-19 patients should be approached in a more holistic way, taking the nervous system into account.Copyright © 2022, Dr. Mladen Stojanovic University Hospital. All rights reserved.
ABSTRACT
Covid-19, one of the coronaviruses, emerged in Wuhan, China, due to zoonotic infection towards the end of December 2019. According to WHO data, Covid-19 has been present among 267.865.289 people in 222 countries, causing death for 5.285.888 (December 12, 2021). Furthermore, these figures are increasing every day. In Turkey, 8.984.407 people have been infected thus far, and 78.602 have died (December 12, 2021). The following questions were investigated in this study: Does Covid-19 affect the use of medicinal and aromatic plants? If it does, what are the changes? What types of herbs are used and in which ways are they used? Who advises people to use these herbs? According to the results, 113 taxa belonging to 61 families and 105 genera were used by the participants at the genus, species and subspecies levels. Herbs that were widely used are Thymus spp., Tilia spp., Salvia spp., Zingiber officinale Roscoe, Mentha spp., Curcuma longa L., Rosa canina L., Camellia sinensis (L.) Kuntze, Lavandula spp., Matricaria spp., respectively. There was a positive and moderate-level relationship between medicinal and aromatic plants before and after COVID-19 and another positive and moderate-level relationship between the frequencies of using medicinal and aromatic plants before and after the pandemic. The relationships were significant for both questionnaire items. Moreover, there was a significant difference between the frequency of use of medicinal and aromatic plants before and after Covid-19. © 2023 Universidad Complutense. All rights reserved.
ABSTRACT
Because of the outbreak of pandemic COVID-19, the economy and financial markets had a sharp decline. Also, based on the lockdown, we saw that amount of production and trade had decreased. This situation continues, and the effect on trade is still an important concern. In this paper, we investigate whether COVID-19 has an effect on trade by means of the real exchange rate in China-EU27 and China-USA. By using J-curve concept, for each trade partner, we use three models, which are ARDL, NARDL, and Multiplier NARDL, using three different data periods considering COVID-19. The results show that inverted J-Curve is proved with the long-run J-Curve effects for both partners, while COVID-19 makes factors favor J-Curve. Although J-Curve was inverted before the pandemic of COVID-9, during the COVID-19, we recognize the effect of J-Curve, which shows that the effect of real exchange rate on trade of China-EU27 and China-USA seems to favor China. © 2022 Informa UK Limited, trading as Taylor & Francis Group.
ABSTRACT
Purpose: The aim of this study was to compare the neurological involvement in Coronavirus 19 (COVID-19) patients with laboratory findings with these cost-free, practical tests. Materials and Methods: Of the 170 patients diagnosed COVID-19, 103 patients could be reached by phone, and neurological symptoms were recorded as three categories. Laboratory tests of the patients and 103 controls whose real-time polymerase chain reaction (RT-PCR) test negative without any chronic disease history and drug use were obtained from the hospital software. Results: White blood cell, neutrophil, lymphocyte, eosinophil, basophil, platelet were lower, monocyte to lymphocyte ratio and platelet to lymphocyte ratio higher in patients than controls. In the group with central nervous system findings, red blood cell and hematocrit counts, in the group with peripheral nervous system findings, lymphocyte and platelet counts and with sleep disturbances and muscle pain group eosinophil counts were lower in patients than those without. Conclusion: COVID-19 patients with neurological symptoms have some hematological abnormalities. The presence of certain hematological findings may be a clue to the emergence of neurological symptoms, and early detection and correction of these hematological abnormalities may be the solution to prevent the development of neurological symptoms in COVID-19.
ABSTRACT
Contracting COVID-19 during pregnancy is a clinical concern as knowledge of altered immunity is limited, and so cases should be considered separately in terms of diagnosis and treatment. Although there is no clear evidence that pregnancy increases the risk of COVID-19, it is thought that susceptibility to infection and the intensification of respiratory symptoms may be increased, given the physiological changes in pregnancy and increased mortality and morbidity in many viral diseases. Accordingly, the management of COVID-19 in pregnant patients and those considered among the high-risk groups represent a challenge for clinicians. Numerous studies of COVID-19 have been published to date or are ongoing, yet pregnant women are generally excluded from clinical studies. Clinical experiences and case reports occupy an important position in literature, and we present hare a case in which the diagnosis of a patient being followed by our clinic was delayed due to the absence of SARS CoV-2 in recurrent upper-respiratory-tract sampling, and whose clinical findings worsened with initial COVID-19 treatment during pregnancy. Her delivery by caesarean section (C-section) was the result of a multidisciplinary decision. We draw attention to the diagnostic process and treatment approach.